Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) (ALYCEmolecular)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Unknown

Conditions

Central Nervous System Lymphoma

Treatments

Other: Retrospective study

Study type

Observational

Funder types

Other

Identifiers

NCT03859544
69HCL17_0692

Details and patient eligibility

About

Central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma (DLBCL) entity with a particularly poor prognosis (median survival less than 3 years). They are still poorly characterized biologically, largely because of their rarity (300 cases / year in France) and the difficulty for obtaining a material of sufficient quality and quantity. It is nevertheless assumed that their pathophysiology is particular, since they develop exclusively in an immunological sanctuary, and that they present some characteristic molecular abnormalities (mutation of MYD88 or TBL1XR1 for example). A collection of 74 PCNSLs has created, clinically annotated, from which frozen material is available in addition to the material fixed and included in paraffin (cohort ALYCE). Informed consent was gathered for all patients. Comparative Genomic Hybridization-array analysis of this cohort has already revealed abnormalities associated with a poor prognosis (unpublished data). The objective of this study is to complete this analysis by sequencing a panel of 96 mutant genes recurrently in DLBCLs and PCNSLs, and the molecular determination of the original cell by the (RT-MLPA) Reverse Transcriptase-Multiplex Ligation-dependent Probe Amplification technique. The integration of genetic, molecular and transcriptomic data may define prognostic markers and open perspectives for translational research in PCNSL.

Enrollment

74 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults
  • With a lymphoma of the central nervous system
  • Patients having signed the consent for the conservation of their samples within the cohort

Exclusion criteria

  • <18 old years
  • Other diagnosis than lymphoma of the central nervous system
  • No consent form signed

Trial contacts and locations

1

Loading...

Central trial contact

Hervé GHESQUIERES, Pr; Pierre SUJOBERT, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems